

Amendments to the Specification:

Please replace the paragraph beginning at page 18, line 29, with the following:

--To facilitate purification of the sialyltransferase polypeptides of the invention, the nucleic acids that encode the sialyltransferase polypeptides can also include a coding sequence for an epitope or "tag" for which an affinity binding reagent is available. Examples of suitable epitopes include the *myc* and V-5 reporter genes; expression vectors useful for recombinant production of fusion polypeptides having these epitopes are commercially available (*e.g.*, Invitrogen (Carlsbad, Calif.) vectors pcDNA3.1/Myc-His and pcDNA3.1/V5-His are suitable for expression in mammalian cells). Additional expression vectors suitable for attaching a tag to the fusion proteins of the invention, and corresponding detection systems are known to those of skill in the art, and several are commercially available (*e.g.*, FLAGTM (DYKDDDK; SEQ ID NO:8; Kodak, Rochester, N.Y.). Another example of a suitable tag is a polyhistidine sequence, which is capable of binding to metal chelate affinity ligands. Typically, six adjacent histidines (SEQ ID NO:6) are used, although one can use more or less than six. Suitable metal chelate affinity ligands that can serve as the binding moiety for a polyhistidine tag include nitrilo-tri-acetic acid (NTA) (Hochuli, E. (1990) "Purification of recombinant proteins with metal chelating adsorbents" In *Genetic Engineering: Principles and Methods*, J.K. Setlow, Ed., Plenum Press, NY; commercially available from Qiagen (Santa Clarita, CA)). The maltose binding protein encoded by the *malE* gene of *E. coli* provides another suitable tag for use in purifying sialyltransferases of the invention; expression vectors for expressing polypeptides that include this tag, as well as amylose resins suitable for their purification are commercially available (*e.g.*, pMAL, New England Biolabs).--

Appl. No. 10/799,016

PATENT

Amdt. dated August 18, 2006

Reply to Office Communication of August 1, 2006

Please cancel the present "SEQUENCE LISTING", pages 1-6, submitted March 11, 2004, and insert therefor the accompanying paper copy of the Substitute Sequence Listing, page numbers 1 to 6, at the end of the application.